

Financial news for AGIO dated on 2020-06-09: The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates

Financial news for AGIO dated on 2020-06-08: Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia

Financial news for AGIO dated on 2020-06-07: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage

Financial news for AGIO dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for AGIO dated on 2020-05-24: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for AGIO dated on 2020-05-19: Agios Highlights Publication Of TIBSOVO Phase 3 Data In The Lancet Oncology Demonstrating 'Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients'

Financial news for AGIO dated on 2020-05-14: Agios Pharma To Present Updated Clinical Proof-Of-Concept Data From Phase 2 Study Of Mitapivat In Thalassemia At European Hematology Association Jun. 12

Financial news for AGIO dated on 2020-05-13: Agios Pharma To Present Updated Data From Phase 1 Study Of Vorasidenib In Non-Enhancing Glioma At ASCO May 29

Financial news for AGIO dated on 2020-05-04: JP Morgan Maintains Overweight on Agios Pharmaceuticals, Raises Price Target to \$82

Financial news for AGIO dated on 2020-04-30: Agios Pharma S-3 Shows Registration For Mixed Securities Shelf Offering, No Size Disclosed

Financial news for AGIO dated on 2020-04-30: Agios Reiterates 2020 TIBSOVO Net US Revenue Guidance Of \$105M-\$115M

Financial news for AGIO dated on 2020-04-30: Agios Pharmaceuticals Q1 EPS \$(0.590) Beats \$(1.670) Estimate, Sales \$87.098M May Not Compare To \$30.830M Estimate

Financial news for AGIO dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for AGIO dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for AGIO dated on 2020-03-30: Agios Announces The European Medicines Agency Committee For Orphan Medicinal Products Issued A Positive Opinion On The Company's Application For Orphan Drug Designation For Its Investigational Medicine Mitapivat As A Potential Treatment For Pyruvate Kinase

Financial news for AGIO dated on 2020-03-25: Agios Says AG-270 Phase 1 Combo Expansion Trials Ongoing

Financial news for AGIO dated on 2020-03-25: Agios Says Research Term Of Metabolic Immuno-Oncology Collaboration Will Conclude At End Of Initial 4-Year Period In May '20

Financial news for AGIO dated on 2020-03-25: Agios Pharma Reports Celgene Declines To Exercise Opt-In Right For AG-270

Financial news for AGIO dated on 2020-03-23: Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a PKR Activator

Financial news for AGIO dated on 2020-03-04: Benzinga's Top Upgrades, Downgrades For March 4, 2020

Financial news for AGIO dated on 2020-03-04: Barclays Initiates Coverage On Agios Pharmaceuticals with Equal-Weight Rating, Announces \$50 Price Target

Financial news for AGIO dated on 2020-02-14: Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticals, Raises Price Target to \$70

Financial news for AGIO dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for AGIO dated on 2020-02-13: Agios Pharmaceuticals Q4 EPS \$(1.6) Beats \$(1.72) Estimate, Sales \$35.44M Beat \$33.72M Estimate

Financial news for AGIO dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for AGIO dated on 2020-01-12: Agios Says In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research Pipeline -

Financial news for AGIO dated on 2020-01-09: Agios Pharma Shares Tick Higher On Spike In Volume As Traders Circulate Article From Spain's Okdiario 'Grifols puts 1.5 billion on the table to buy 50% of Agios'

Financial news for AGIO dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for AGIO dated on 2019-12-17: 30 Stocks Moving in Tuesday's Pre-Market Session

Financial news for AGIO dated on 2019-12-16: 5 Stocks Moving In Monday's After-Hours Session

Financial news for AGIO dated on 2019-12-16: Agios Pharma shares are trading higher after the company was granted Breakthrough Therapy designation from the FDA for TIBSOVO for the treatment of adult patients with relapsed or refractory MDS with an IDH1 mutation.

Financial news for AGIO dated on 2019-12-16: Agios Pharma Reports FDA Breakthrough Therapy Designation For TIBSOVO For Treatment Of Adult Patients With Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

Financial news for AGIO dated on 2019-12-09: Agios Pharma Offers Updated Data From Mitapivat From Extension Phase Of DRIVE PK Study In Patients With Pyruvate Kinase Deficiency

Financial news for AGIO dated on 2019-12-09: BMO Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to \$49

Financial news for AGIO dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for AGIO dated on 2019-12-08: Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results at ASH 2019

Financial news for AGIO dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correlio Awaits Adcom Ruling

Financial news for AGIO dated on 2019-12-04: JP Morgan Maintains Overweight on Agios Pharmaceuticals, Lowers Price Target to \$68

Financial news for AGIO dated on 2019-11-27: Agios Pharmaceuticals Option Alert: Jan 17 \$40 Calls Sweep (2) near the Ask: 500 @ \$3.201 vs 55 OI; Ref=\$39.17

Financial news for AGIO dated on 2019-11-26: Benzinga's Top Upgrades, Downgrades For November 26, 2019

Financial news for AGIO dated on 2019-11-26: Cantor Fitzgerald Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces \$64 Price Target

Financial news for AGIO dated on 2019-11-22: Agios Highlights Presentation New Pharmacodynamic And Response Data From Both Cohorts Of Perioperative Study Of Vorasidenib And TIBSOVO In Patients With IDH1 Mutant Positive Low-Grade Glioma

Financial news for AGIO dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for AGIO dated on 2019-11-17: The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

Financial news for AGIO dated on 2019-11-08: 10 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AGIO dated on 2019-11-08: 30 Stocks Moving in Friday's Pre-Market Session

Financial news for AGIO dated on 2019-11-08: Agios Prices 8.25M Share Public Offering of Common Stock @\$31/Share

Financial news for AGIO dated on 2019-11-07: 30 Stocks Moving in Thursday's Pre-Market Session

Financial news for AGIO dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for AGIO dated on 2019-11-07: 14 Stocks To Watch For November 7, 2019

Financial news for AGIO dated on 2019-11-06: Agios Announces 7.5M Share Common Stock Offering

Financial news for AGIO dated on 2019-11-05: Citigroup Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to \$64

Financial news for AGIO dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for AGIO dated on 2019-10-31: Agios Pharmaceuticals Earlier Reported Q3 EPS \$(1.81) Misses \$(1.8) Estimate, Sales \$26.024M Miss \$32.99M Estimate

Financial news for AGIO dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for AGIO dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for AGIO dated on 2019-10-27: Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

Financial news for AGIO dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for AGIO dated on 2019-10-09: Stocks That Hit 52-Week Lows On Wednesday

Financial news for AGIO dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for AGIO dated on 2019-09-30: Stocks That Hit 52-Week Lows On Monday

Financial news for AGIO dated on 2019-09-30: Agios Pharma Reports Data From Phase 3 ClarIDHy Trial Of TIBSOVO Showed Significant Improvement In Progression-Free Survival Compared To Placebo

Financial news for AGIO dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for AGIO dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for AGIO dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for AGIO dated on 2019-09-23: Benzinga's Top Upgrades, Downgrades For September 23, 2019

Financial news for AGIO dated on 2019-09-23: Guggenheim Upgrades Agios Pharmaceuticals to Buy

Financial news for AGIO dated on 2019-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2019

Financial news for AGIO dated on 2019-09-12: BMO Capital Initiates Coverage On Agios Pharmaceuticals with Outperform Rating, Announces \$45 Price Target

Financial news for AGIO dated on 2019-09-10: The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

Financial news for AGIO dated on 2019-09-04: Agios Highlights Publication Of Data For Mitapivat From Core And Extension Phases Of DRIVE PK Study In Patients With Pyruvate Kinase Deficiency In The New England Journal Of Medicine

Financial news for AGIO dated on 2019-09-04: Stocks That Hit 52-Week Lows On Wednesday

Financial news for AGIO dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for AGIO dated on 2019-08-29: The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

Financial news for AGIO dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for AGIO dated on 2019-08-06: Alamos Gold Option Alert: Mar 20 \$10 Calls Sweep (15) near the Ask: 500 @ \$0.5 vs 174 OI; Ref=\$7.54

Financial news for AGIO dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for AGIO dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for AGIO dated on 2019-08-01: Agios Pharmaceuticals Q2 EPS \$(1.87) Misses \$(1.7) Estimate, Sales \$26.221M Miss \$27.05M Estimate

Financial news for AGIO dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for AGIO dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for AGIO dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for AGIO dated on 2019-06-03: Agios Reports Presented Updated Data From Phase 1 Studies Of TIBSOVO In Newly-Diagnosed Adult Patients With IDH1 Mutant Acute Myeloid Leukemia Not Eligible For Intensive Chem

Financial news for AGIO dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for AGIO dated on 2019-05-23: Goldman Sachs Assumes Agios Pharmaceuticals, Inc. - Common Stock at Neutral, Announces Price Target \$55

Financial news for AGIO dated on 2019-05-17: 63 Biggest Movers From Yesterday

Financial news for AGIO dated on 2019-05-16: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for AGIO dated on 2019-05-16: Agios Pharmaceuticals shares are trading higher after the company achieved its primary endpoint for the Phase 3 ClarIDHy trial of TIBSOVO.

Financial news for AGIO dated on 2019-05-16: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for AGIO dated on 2019-05-16: The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

Financial news for AGIO dated on 2019-05-15: 6 Stocks Moving In Wednesday's After-Hours Session

Financial news for AGIO dated on 2019-05-15: Agios Pharmaceuticals shares are trading higher after the company reported its Phase 3 ClarIDHy Trial of TIBSOVO achieved its primary endpoint in previously treated IDH1 mutant Cholangiocarcinoma patients.

Financial news for AGIO dated on 2019-05-15: Agios Reports Randomized Phase 3 ClarIDHy Trial Of TIBSOVO Achieved Primary Endpoint In Previously-Treated IDH1 Mutant Cholangiocarcinoma Patients

Financial news for AGIO dated on 2019-05-02: Agios Reports FDA Approval Of Supplemental New Drug Application For TIBSOVO As Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

Financial news for AGIO dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for AGIO dated on 2019-05-02: Agios Pharmaceuticals Q1 EPS \$(1.59)

Beats \$(1.75) Estimate, Sales \$30.227M Beat \$22.69M Estimate

Financial news for AGIO dated on 2019-03-27: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

Financial news for AGIO dated on 2019-03-26: Agios Pharma Reports Received FDA Breakthrough Therapy Designation For TIBSOVO In Combo With Azacitidine For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy

Financial news for AGIO dated on 2019-02-25: Agios Pharma Gives an Update on its Phase 1 Study of Ivosidenib in Combination with Azacitidine

Financial news for AGIO dated on 2019-02-20: Oppenheimer Earlier Assumed Agios Pharmaceuticals at Perform

Financial news for AGIO dated on 2019-02-20: Agios Announces FDA Acceptance Of Supplemental New Drug Application For TIBSOVO For Treatment Of Patients With Newly Diagnosed Acute Myeloid Leukemia With An IDH1 Mutation Not Eligible For Standard Therapy

Financial news for AGIO dated on 2019-02-15: Leerink Swann Upgrades Agios Pharmaceuticals to Outperform, Announces \$80 Target

Financial news for AGIO dated on 2019-02-14: Agios Pharmaceuticals shares are trading higher after the company reported Q4 EPS of \$(1.58), beating the \$(1.62) estimate and sales of \$30.013 million, beating the \$22.04 million estimate.

Financial news for AGIO dated on 2019-02-14: Agios Pharmaceuticals Earlier Reported Q4 EPS \$(1.58) Beats \$(1.62) Estimate, Sales \$30.013M Beat \$22.04M Estimate

Financial news for AGIO dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for AGIO dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for AGIO dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for AGIO dated on 2018-12-17: Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Financial news for AGIO dated on 2018-12-04: 56 Biggest Movers From Yesterday

Financial news for AGIO dated on 2018-12-03: Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)

Financial news for AGIO dated on 2018-12-03: Agios Pharma To Offer Updated Phase 1 Study Data Of Ivosidenib, Enasidenib In Combo With Standard Induction, Consolidation Chemotherapy In Newly-Diagnosed AML Patients With IDH Mutation

Financial news for AGIO dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for AGIO dated on 2018-11-29: Watching Celgene, Agio Pharma Shares Following Warning From FDA Symptoms Of Serious Condition Affecting Blood Cells Not Being Recognized With IDHIFA

Financial news for AGIO dated on 2018-11-16: Agios Pharma Offers Updated Data From Phase 1 Dose-Escalation Study Of AG-881 In Patients With IDH Mutant Positive Advanced Glioma: Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining

Financial news for AGIO dated on 2018-11-01: Agios Pharmaceuticals Q3 EPS \$(1.63) Misses \$(1.62) Estimate, Sales \$15.198M Miss \$19.12M Estimate

Financial news for AGIO dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for AGIO dated on 2018-09-25: Leerink Swann Initiates Coverage On Agios Pharmaceuticals with Market Perform Rating, Announces \$80 Price Target

Financial news for AGIO dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for AGIO dated on 2018-09-05: 26 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AGIO dated on 2018-09-05: Agios Pharmaceuticals 8-K Shows On Sept 4, Co. And Celgene Agreed To Terminate Collaboration And License Deal

Financial news for AGIO dated on 2018-09-04: Agios Pharma Reports CEO David Schenkein To Transition To Role As Exec. Chair; Jackie Fouse Named Replacement As CEO

Financial news for AGIO dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for AGIO dated on 2018-08-02: Agios Pharmaceuticals Q2 EPS \$(1.19) Beats \$(1.55) Estimate, Sales \$40.414M Beat \$11.28M Estimate

Financial news for AGIO dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for AGIO dated on 2018-07-24: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AGIO dated on 2018-07-20: Hearing Agios Prices Tibsovo At \$26,115/Month

Financial news for AGIO dated on 2018-07-20: FDA Says Agios Pharmaceutical' Tibsovo Prescribing Info Includes Boxed Warning That A Possibly Fatal Adverse Reaction Known As Differentiation Syndrome Can Occur

Financial news for AGIO dated on 2018-07-20: Agios Pharmaceuticals Reports FDA Grants Approval of TIBSOVO

Financial news for AGIO dated on 2018-06-26: Agios And CStone Pharmaceuticals Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Ivosidenib In Greater China; Agios To Receive \$12M Upfront Payment And Is Eligible For Up To \$412M In Milestones

Financial news for AGIO dated on 2018-06-21: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

Financial news for AGIO dated on 2018-06-04: Agios Pharmaceuticals Reports Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidin; Reports ORR of 78%, CR Rate of 44% and CR/CRi/CRp Rate of 65% in the Ivosidenib Arm; Molecular Clearance Observed in 7 Out of 21 Patients

Financial news for AGIO dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for AGIO dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for AGIO dated on 2018-05-31: Investors Should Own Agios For 'The Next Several Years,' Analyst Says

Financial news for AGIO dated on 2018-05-31: PiperJaffray Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces \$125 Price Target

Financial news for AGIO dated on 2018-05-23: Citigroup Earlier Initiated Coverage On Agios Pharmaceuticals with Buy Rating

Financial news for AGIO dated on 2018-05-15: 13F From Cooperman's Omega Shows New Stake In Agios Pharma

Financial news for AGIO dated on 2018-05-04: Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

Financial news for AGIO dated on 2018-05-04: Agios Pharmaceuticals Q1 EPS \$(1.63), Inline, Sales \$8.762M Miss \$10.6M Estimate

Financial news for AGIO dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for AGIO dated on 2018-04-11: 7 Biggest Price Target Changes For Wednesday

Financial news for AGIO dated on 2018-04-11: Credit Suisse Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to \$95.00

Financial news for AGIO dated on 2018-03-19: Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or

Lymphoma with an MTAP Deletion

Financial news for AGIO dated on 2018-02-15: Agios Pharmaceuticals Reports FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib, PDUFA date set for August 21, 2018

Financial news for AGIO dated on 2018-02-15: Credit Suisse Maintains Outperform on Agios Pharmaceuticals Inc, Raises price target to \$80.00

Financial news for AGIO dated on 2018-02-15: JP Morgan Maintains Overweight on Agios Pharmaceuticals Inc, Raises price target to \$85.00

Financial news for AGIO dated on 2018-02-14: Agios Shares Fall ~\$2 Over Last Min. As Oppenheimer Downgrades To Perform

Financial news for AGIO dated on 2018-02-14: Agios Reports Q4 EPS \$(1.81) vs \$(1.66) Est., Sales \$9.79M vs \$13.3M Est.

Financial news for AGIO dated on 2018-01-19: Agios Shares Up 5.87% At \$72.30, Despite Announcing A 7.09M Share Common Stock Offering Priced at \$67/Share

Financial news for AGIO dated on 2018-01-19: A Survey Of Celgene's M&A Strategy

Financial news for AGIO dated on 2018-01-19: Agios Prices ~7.09M Share Public Offering of Common Stock @\$67/Share

Financial news for AGIO dated on 2018-01-17: Agios Pharma Reports \$400M Common Stock Offering

Financial news for AGIO dated on 2018-01-08: Agios Pharma Shares Down ~1% Mon.; Co. Earlier Outlined Key '18 Priorities

Financial news for AGIO dated on 2017-12-26: Agios Submits New Drug Application to the FDA for Ivosidenib, Announces FDA Clearance of an Investigational NDA for AG-270

Financial news for AGIO dated on 2017-12-19: Oppenheimer Serves Up 29 Top Stock Ideas For January

Financial news for AGIO dated on 2017-12-11: UPDATE: Agios Highlights 'In 125 R/R AML Patients From the Primary Analysis Set, Combined CR+CRh Rate of 30.4% with a Median Duration of 8.2 Months'

Financial news for AGIO dated on 2017-12-11: Agios Pharma Offers First Expansion Data, Updated Dose-Escalation Data Supporting NDA Submission For IDH1m R/R AML By Year End '17

Financial news for AGIO dated on 2017-12-11: Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency at #ASH2017

Financial news for AGIO dated on 2017-11-30: Oppenheimer's Top Stock Picks For December

Financial news for AGIO dated on 2017-11-17: Agios Pharma Gives Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib

Financial news for AGIO dated on 2017-11-01: Agios Pharma Reports Q3 EPS \$(1.59) vs \$(1.79) Est., Sales \$11.358M vs \$9.8M Est.

Financial news for AGIO dated on 2017-10-16: 29 Top Stock Ideas For October And Beyond

Financial news for AGIO dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for AGIO dated on 2017-09-01: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Financial news for AGIO dated on 2017-09-01: Oppenheimer Presents New Menu Of Top Picks

Financial news for AGIO dated on 2017-08-02: Benzinga's Top Upgrades, Downgrades For August 2, 2017

Financial news for AGIO dated on 2017-08-02: Leerink Swann Upgrades Agios Pharmaceuticals to Outperform

Financial news for AGIO dated on 2017-08-01: Meg Tirrell Tweets: SunTrust's Yatin

Suneja says Idhifa monthly price is \$10K more than he modeled \$CELG \$AGIO

Financial news for AGIO dated on 2017-08-01: Key FDA Events To Watch Out For In August 2017

Financial news for AGIO dated on 2017-08-01: FDA Has Approved Idhifa For Treatment Of Adult Patients with Relapsed/Refractory AML

Financial news for AGIO dated on 2017-08-01: Adam Feuerstein Tweets: \$CELG \$AGIO - FDA approves enasidenib (Idhifa) for r/r AML. Early.

Financial news for AGIO dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for AGIO dated on 2017-06-29: Oppenheimer Analysts Release 28 Best Ideas List

Financial news for AGIO dated on 2017-06-26: 12 Biggest Mid-Day Losers For Monday

Financial news for AGIO dated on 2017-06-26: Benzinga's Top Upgrades, Downgrades For June 26, 2017

Financial news for AGIO dated on 2017-06-26: Janney Capital Downgrades Agios Pharmaceuticals to Neutral

Financial news for AGIO dated on 2017-06-24: Agios Pharma Announces New Data from Phase 1/2 Trial of Oral IDHIFA Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML #EHA2017

Financial news for AGIO dated on 2017-06-24: Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as First Disease-modifying Treatment for Patients with PKR #EHA2017

Financial news for AGIO dated on 2017-06-05: Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data

Financial news for AGIO dated on 2017-06-03: Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma #ASCO17

Financial news for AGIO dated on 2017-05-18: Thermo Fisher Signs Development Agreement with Agios Pharmaceuticals for Next-Gen Sequencing Oncology Companion Diagnostic in Cholangiocarcinoma

Financial news for AGIO dated on 2017-05-04: Agios Pharma Q1 EPS \$(1.56) vs \$(1.71) Est, Sales \$10.51M vs \$8.07M Est

Financial news for AGIO dated on 2017-04-27: Agios Pharma Reports Entering Into of Exclusive License Deal for Novel Small Molecules for Cancer Metabolism Target, Includes \$3M Upfront Payment, Potential Future Milestone Payments for Up to \$17M Per Licensed Product

Financial news for AGIO dated on 2017-04-18: Agios Announces Prices ~5.05M Share Offering of Common Stock @\$49.50/Share

Financial news for AGIO dated on 2017-04-17: Agios Reports Proposed Offering of 4.5M Shares of Common Stock

Financial news for AGIO dated on 2017-03-13: Agios Pharma Reports MTAP Pathway Research Program as Development Program, Development Candidate Under Master Research & Collaboration Deal with Celgene

Financial news for AGIO dated on 2017-02-16: Hearing Agios Pharmaceuticals Upgraded To Buy At Janney With PT Of \$57

Financial news for AGIO dated on 2017-02-16: Agios Reports Q4 EPS \$(1.34) vs. \$(1.51) Est., Rev. \$22.6M vs. \$10.89M Est.

Financial news for AGIO dated on 2017-01-17: Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch

Financial news for AGIO dated on 2017-01-17: Benzinga's Top Upgrades, Downgrades For January 17, 2017

Financial news for AGIO dated on 2017-01-17: Oppenheimer Upgrades Agios Pharmaceuticals to Outperform

Financial news for AGIO dated on 2017-01-09: Agios Announces AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017

Financial news for AGIO dated on 2016-12-27: Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Financial news for AGIO dated on 2016-12-16: Agios Pharma Shares Crushed Under Weight Of Clinical Setback

Financial news for AGIO dated on 2016-12-16: Mid-Morning Market Update: Markets Open Higher; Adobe Beats Q4 Expectations

Financial news for AGIO dated on 2016-12-16: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for AGIO dated on 2016-12-15: Agios Pharma Shares Resume Trade, Now Down ~17%

Financial news for AGIO dated on 2016-12-15: Agios Pharma Shares to Resume at 4:30 p.m. EST

Financial news for AGIO dated on 2016-12-15: Agios Provides Update on PKR Program, Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback

Financial news for AGIO dated on 2016-12-06: Agios Pharmaceuticals Shares Down 4% Midday On Above Average Volume; Co Earlier Reported Clinical Data From Phase 1 Trial Of AG-120, Some Investors Showing Safety Concern Over Hepatitis Reported In A Single Patient

Financial news for AGIO dated on 2016-12-05: Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies at ASH 2016

Financial news for AGIO dated on 2016-12-05: Mid-Afternoon Market Update: NeuroDerm Surges Following Meeting With FDA; Cerecor Shares Slide

Financial news for AGIO dated on 2016-12-05: 10 Biggest Mid-Day Losers For Monday

Financial news for AGIO dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for AGIO dated on 2016-12-05: Mid-Day Market Update: NASDAQ Up 1%; Ocean Power Technologies Shares Spike Higher

Financial news for AGIO dated on 2016-12-05: CNBC's Meg Tirrell Tweets: #ASH16 stocks looking largely opposite of last year. So far: \$KITE +9.4% \$JUNO +6.6% \$ONCE +2.5% On flip side: \$GBT -3.3% \$AGIO -12%

Financial news for AGIO dated on 2016-12-05: Mid-Morning Market Update: Markets Open Higher; Consolidated Communications to Acquire FairPoint Communications

Financial news for AGIO dated on 2016-12-05: Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency at ASH 2016

Financial news for AGIO dated on 2016-11-29: Oppenheimer Initiates Coverage On Agios Pharmaceuticals at Perform

Financial news for AGIO dated on 2016-11-18: Companies Presenting Data At Society For Neuro-Oncology Meeting Today Include Agios Pharmaceuticals, Celgene, Cellidex Therapeutics, & NewLink Genetics

Financial news for AGIO dated on 2016-11-18: Agios Pharma Announces Phase 1 Data For AG-120

Financial news for AGIO dated on 2016-11-03: Agios Reports Q3 EPS \$(1.63) vs. Est. \$(1.52)

Financial news for AGIO dated on 2016-10-12: Celgene, Agios Report Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML

Financial news for AGIO dated on 2016-09-15: 15 Biggest Mid-Day Gainers For Thursday

Financial news for AGIO dated on 2016-09-15: Benzinga's Volume Movers

Financial news for AGIO dated on 2016-09-15: Agios Pharmaceuticals Prices 3,370,786 Shares Offering @ \$44.50/Share

Financial news for AGIO dated on 2016-09-14: 12 Biggest Mid-Day Losers For Wednesday

Financial news for AGIO dated on 2016-09-14: 12 Stocks Moving In Wednesday's Pre-

Market Session

Financial news for AGIO dated on 2016-09-13: Agios Pharmaceuticals To Offer \$150M Common Stock

Financial news for AGIO dated on 2016-09-09: Option Alert: Agios Pharmaceuticals Nov \$50 Calls at the bid: 1823 @ 2.5 vs. Open Interest 1170

Financial news for AGIO dated on 2016-09-07: Wednesday's Market Wrap: Major Averages Close Mixed

Financial news for AGIO dated on 2016-09-07: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for AGIO dated on 2016-09-07: Mid-Day Market Update: Sprouts Farmers Market Drops Following Guidance Cut; Cogentix Medical Shares Surge

Financial news for AGIO dated on 2016-09-07: Benzinga's Volume Movers

Financial news for AGIO dated on 2016-09-07: Mid-Morning Market Update: Markets Mostly Flat; HD Supply Misses Q2 Views

Financial news for AGIO dated on 2016-09-07: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AGIO dated on 2016-09-07: Celgene, Agios To Submit NDA For enasidenib Based On Ongoing Phase 1/2 Study

Financial news for AGIO dated on 2016-08-30: Option Alert: Agios Pharmaceuticals Feb 17 \$50 Calls Sweep at the ask: 1000 @ 3.8 vs. Open Interest 137; Ref=\$37.20

Financial news for AGIO dated on 2016-08-19: Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates

Financial news for AGIO dated on 2016-08-19: BTIG Research Initiates Coverage on Agios Pharmaceuticals at Neutral

Financial news for AGIO dated on 2016-08-16: Agios Names Andrew Hirsch CFO

Financial news for AGIO dated on 2016-08-08: Q2 Earnings Report Card: Biotech

Financial news for AGIO dated on 2016-08-04: Agios Pharmaceuticals Reports Q2 EPS \$(1.47) vs. Est. \$(0.48), Rev. \$6.9M

Financial news for AGIO dated on 2016-06-13: Canaccord Sees \$40 In Upside For Agios, Upgrades To Buy

Financial news for AGIO dated on 2016-06-13: JPMorgan Upgrades Agios Pharma To Overweight Despite Last Week's 25% Decline

Financial news for AGIO dated on 2016-06-13: 6 Largest Price Target Changes For Monday

Financial news for AGIO dated on 2016-06-13: The Market In 5 Minutes: Microsoft-LinkedIn, And Some Major iPhone News

Financial news for AGIO dated on 2016-06-13: Goldman Sachs: 3 Questions For Agios Pharmaceuticals

Financial news for AGIO dated on 2016-06-13: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for AGIO dated on 2016-06-13: Canaccord Genuity Upgrades Agios Pharmaceuticals to Buy

Financial news for AGIO dated on 2016-06-13: Agios Pharmaceuticals Upgraded From Neutral To Overweight AT JP Morgan, PT Raised From \$50 to \$62

Financial news for AGIO dated on 2016-06-11: Agios Announces AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency

Financial news for AGIO dated on 2016-06-10: Option Alert: SWEEP (SELL) - AGIO June \$50 Call- 2000 @ 6.3 in 3 orders. 2000 traded. OI: 959

Financial news for AGIO dated on 2016-06-09: 11 Biggest Mid-Day Losers For Thursday

Financial news for AGIO dated on 2016-06-09: Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers, Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing

Financial news for AGIO dated on 2016-05-19: Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of EHA

Financial news for AGIO dated on 2016-05-17: UPDATE: Agios Pro-Forma Cash Balance as of Mar. 31, 2016 \$556M

Financial news for AGIO dated on 2016-05-17: Agios Sees FY16 Ending Cash Position of \$390M+

Financial news for AGIO dated on 2016-05-17: UPDATE: Agios Will Receive Upfront Cash Payment of \$200M Plus Potential for Added Payments if Certain Development, Regulatory Milestones Achieved

Financial news for AGIO dated on 2016-05-17: Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement

Financial news for AGIO dated on 2016-05-17: Agios, Celgene Report New Collab in Metabolic Immuno-Oncology, Amend Certain Rights from '10 Deal

Financial news for AGIO dated on 2016-05-05: Agios Reports Q1 EPS \$(0.61) vs. Est. \$(0.79), Rev. \$31.281M vs. Est. \$20.94M

Financial news for AGIO dated on 2016-03-30: Benzinga's Top Initiations

Financial news for AGIO dated on 2016-03-30: Agios Initiates Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Financial news for AGIO dated on 2016-03-30: SunTrust Robinson Humphrey Initiates Coverage on Agios Pharmaceuticals at Buy, Announces \$57.00 PT

Financial news for AGIO dated on 2016-03-24: 23 Ways To Say 'I'm A Contrarian Investor'

Financial news for AGIO dated on 2016-03-02: Benzinga's Top Initiations

Financial news for AGIO dated on 2016-03-02: Janney Capital Initiates Coverage on Agios Pharmaceuticals at Neutral

Financial news for AGIO dated on 2016-02-18: Agios Reports Q4 EPS \$(1.08) vs. Est. \$(0.50)

Financial news for AGIO dated on 2016-01-21: Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks

Financial news for AGIO dated on 2016-01-20: Credit Suisse Initiates Coverage on Agios Pharmaceuticals at Outperform, Announces \$75.00 PT

Financial news for AGIO dated on 2015-12-18: Agios Announces Starts of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Financial news for AGIO dated on 2015-12-07: Stocks Hitting 52-Week Lows

Financial news for AGIO dated on 2015-12-07: Mid-Morning Market Update: Markets Open Lower; Keurig Green Mountain Agrees To Be Taken Private For \$92/Share

Financial news for AGIO dated on 2015-12-07: Morning Market Losers

Financial news for AGIO dated on 2015-12-07: Leerink Swann Downgrades Agios Pharmaceuticals to Market Perform

Financial news for AGIO dated on 2015-12-06: Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies at #ASH2015

Financial news for AGIO dated on 2015-12-05: Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies at #ASH15

Financial news for AGIO dated on 2015-11-08: Agios Announces Safety Profile Confirmed in Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

Financial news for AGIO dated on 2015-11-05: Agios Reports Q3 EPS \$(1.07) vs. Est. \$(0.88), Rev. \$5.48M vs. Est. \$17.21M

Financial news for AGIO dated on 2015-10-26: Agios to Show Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC

Financial news for AGIO dated on 2015-10-19: Here's Why Biotechs Fell On Monday

Financial news for AGIO dated on 2015-10-19: Canaccord's Newman Cuts Agios Pharma Price Target from \$93 to \$70; Warns of 'Cautious AG-120 solid tumor commentary at analyst day'

Financial news for AGIO dated on 2015-10-16: UPDATE: Agios Reports Frontline Combo Development Strategy for AG-221, AG-120

Financial news for AGIO dated on 2015-10-16: Agios Pharma Reports Phase 3 Study of AG-221 in IDH2 Leukemia Initiated

Financial news for AGIO dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for AGIO dated on 2015-08-21: In new note to subscribers, CMT Christian Tharp making bet that 15-20% correction is coming

Financial news for AGIO dated on 2015-07-22: Northland Securities Initiates Coverage on Agios Pharmaceuticals at Outperform, Announces \$132.00 PT

Financial news for AGIO dated on 2015-06-24: Agios Reports First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Financial news for AGIO dated on 2015-06-23: Agios Appoints Maykin Ho To Board of Directors

Financial news for AGIO dated on 2015-06-15: Agios Pharma Dip Below \$100 Level as Hearing Canaccord Analyst Offers Warning

Financial news for AGIO dated on 2015-06-15: Roth Capital's Chattopadhyay Believes Agios Pharma's AG-221 'Continues to be Compelling,' Maintains Neutral, \$114 Target

Financial news for AGIO dated on 2015-06-12: Mid-Afternoon Market Update: Wingstop Shares Surge in Stock Market Debut; ExOne Shares Tumble

Financial news for AGIO dated on 2015-06-12: Mid-Day Market Update: Restoration Hardware Rises On Earnings Beat; Agios Pharmaceuticals Shares Slide

Financial news for AGIO dated on 2015-06-12: Mid-Morning Market Update: Markets Open Lower; Twitter CEO Dick Costolo Resigns

Financial news for AGIO dated on 2015-06-12: Morning Market Losers

Financial news for AGIO dated on 2015-06-12: Benzinga's Top #PreMarket Gainers

Financial news for AGIO dated on 2015-06-12: US Stock Futures Slide Ahead Of Economic Data

Financial news for AGIO dated on 2015-06-12: Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

Financial news for AGIO dated on 2015-06-10: Agios Pharmaceuticals Reports FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

Financial news for AGIO dated on 2015-05-18: Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

Financial news for AGIO dated on 2015-05-07: Agios Pharma Updates Late-Stage Clinical Development For AG-221 & AG-120

Financial news for AGIO dated on 2015-05-07: Agios Reports Q1 EPS \$(0.13) vs. Est. \$(0.92), Rev. \$34.2M vs. Est. \$10.86M; Estimates May Not Be Comparable

Financial news for AGIO dated on 2015-05-06: Investing In Personalized Cancer Treatment

Financial news for AGIO dated on 2015-05-05: Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestle Health Science and Bayer CropScience

Financial news for AGIO dated on 2015-04-30: Canaccord Downgrading Agios To Hold

Financial news for AGIO dated on 2015-04-30: Canaccord Genuity Downgrades Agios

Pharmaceuticals to Hold, Lowers PT to \$103.00

Financial news for AGIO dated on 2015-04-29: Agios Pharmaceuticals Chooses Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

Financial news for AGIO dated on 2015-04-20: Oppenheimer Initiates Coverage on Agios Pharmaceuticals at Perform

Financial news for AGIO dated on 2015-03-26: Agios Pharmaceuticals Has Been Plummeting

Financial news for AGIO dated on 2015-03-24: UPDATE: Agios Plans TO Initiate A Phase 2 Clincical Trial In Hq of 2015

Financial news for AGIO dated on 2015-03-24: Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency

Financial news for AGIO dated on 2015-02-17: Morning Market Losers

Financial news for AGIO dated on 2015-02-17: Agios Pharma Shares Fall 5.5% Premarket Following Wider than Expected Loss

Financial news for AGIO dated on 2015-02-17: Agios Pharma Reports EPS Loss \$0.76 Vs Est Loss \$0.58, Sales \$14.6M Vs Est \$10.94M

Financial news for AGIO dated on 2015-02-17: Earnings Scheduled For February 17, 2015

Financial news for AGIO dated on 2015-01-28: UPDATE: Citigroup Downgrades Agios Pharmaceuticals As Valuation Is Stretched

Financial news for AGIO dated on 2015-01-28: Benzinga's Top #PreMarket Losers

Financial news for AGIO dated on 2015-01-28: Citigroup Downgrades Agios Pharmaceuticals to Neutral

Financial news for AGIO dated on 2015-01-12: Agios Announces That Celgene Has Agreed To Exercise Its Option To License AG-120 Under Global Strategic Collaboration

Financial news for AGIO dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for AGIO dated on 2014-12-29: The Top 5 Biotech Gainers Of 2014

Financial news for AGIO dated on 2014-12-23: Biotech Stocks Sell Off, ETFs Fall Over 5%

Financial news for AGIO dated on 2014-12-12: CNBC's Stock Pops & Drops From December 11

Financial news for AGIO dated on 2014-12-10: Agios Pharmaceuticals Prices ~1.986M Share Offering @\$110.75/Share

Financial news for AGIO dated on 2014-12-09: Agios Press Release Confirms Offering of Up to \$175M in Common Shares

Financial news for AGIO dated on 2014-12-09: Filing from Agios Pharma Shows Registration for Automatic Mixed Securities Shelf Offering

Financial news for AGIO dated on 2014-12-08: These 4 Biotech Stocks Have Been On Fire

Financial news for AGIO dated on 2014-12-08: Agios Reports Positive Phase 1 Data In Healthy Volunteers For AG-348

Financial news for AGIO dated on 2014-12-08: Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For \$102/Share

Financial news for AGIO dated on 2014-12-08: Morning Market Movers

Financial news for AGIO dated on 2014-12-08: Celgene Shares Rise 2% Premarket Following ASH Presentations, Extension of Collaboration with Agios

Financial news for AGIO dated on 2014-12-08: Benzinga's Top #PreMarket Gainers

Financial news for AGIO dated on 2014-12-08: Agios Pharma Reports Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to Apr. '16

Financial news for AGIO dated on 2014-12-07: Agios Announces Positive Data from Ongoing Phase 1 Trial of AG-221 at ASH Annual Meeting

Financial news for AGIO dated on 2014-12-04: UPDATE: MLV Initiates Coverage On Agios Pharmaceuticals

Financial news for AGIO dated on 2014-12-04: MLV & Co. Initiates Coverage on Agios Pharmaceuticals at Buy, Announces \$123.00 PT

Financial news for AGIO dated on 2014-12-02: JP Morgan Downgrades Agios Pharmaceuticals to Neutral, Raises PT to \$90.00

Financial news for AGIO dated on 2014-12-01: Could This Biotech Stock Fall Even Further?

Financial news for AGIO dated on 2014-11-20: CNBC's Stock Pops & Drops From November 19

Financial news for AGIO dated on 2014-11-19: Mid-Day Gainers From November 19: Stage Stores, China Distance Education, Oplink, Agios Pharmaceuticals, Staples

Financial news for AGIO dated on 2014-11-19: Benzinga's Volume Movers

Financial news for AGIO dated on 2014-11-18: UPDATE: Agios Pharmaceuticals Announces Positive Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in AML

Financial news for AGIO dated on 2014-11-18: Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia

Financial news for AGIO dated on 2014-11-12: Canaccord Genuity Initiates Coverage on Agios Pharmaceuticals at Buy, Announces \$97.00 PT

Financial news for AGIO dated on 2014-11-10: Citigroup Maintains Hold on Agios Pharmaceuticals, Raises PT to \$93.00

Financial news for AGIO dated on 2014-11-07: Earnings Scheduled For November 7, 2014

Financial news for AGIO dated on 2014-10-21: Midday Gainers From October 21: Aircastle, American Airlines, Agios Pharmaceuticals

Financial news for AGIO dated on 2014-10-21: Agios Pharma Reports Initiation of Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with IDH2 Mutation

Financial news for AGIO dated on 2014-10-15: Agios Pharmaceuticals Announces Initiation Of Four Expansion Cohorts In Phase 1 Study Of AG-221

Financial news for AGIO dated on 2014-09-27: Agios Pharmaceuticals Inc, Altria Group Inc Highlight CNBC's Stock Pops & Drops From September 26

Financial news for AGIO dated on 2014-09-26: Benzinga's Volume Movers

Financial news for AGIO dated on 2014-09-26: Shares of Agios Pharma Getting a Cramer Pop Right Now -- He Just Mentioned on CNBC

Financial news for AGIO dated on 2014-09-26: Agios Pharmaceuticals Share Spike Higher; Positive Jim Cramer/CNBC Comments

Financial news for AGIO dated on 2014-09-26: Agios Pharmaceuticals To Present Clinical Data From AG-120 Ongoing Phase 1 Study In Hematologic Malignancies At EORTC-NCI-AACR 2014

Financial news for AGIO dated on 2014-09-17: Benzinga's Volume Movers

Financial news for AGIO dated on 2014-09-17: Morning Market Movers

Financial news for AGIO dated on 2014-09-17: Benzinga's Top #PreMarket Gainers

Financial news for AGIO dated on 2014-09-16: Shares of Agios Pharmaceuticals Rise 10% After-Hours on Positive Jim Cramer/Mad Money Comments

Financial news for AGIO dated on 2014-08-13: Agios Pharma Announces Fast Track Designation For AG-221

Financial news for AGIO dated on 2014-08-07: Agios Pharmaceuticals Reports Q2 EPS of \$(0.54) vs \$(0.41) Est

Financial news for AGIO dated on 2014-07-01: Citigroup Initiates Coverage on Agios Pharmaceuticals at Buy, Announces \$58.00 PT

Financial news for AGIO dated on 2014-06-24: Agios Pharmaceuticals Directr Maraganore Buys 2,300 Shares @\$43.98/Share -Form 4

Financial news for AGIO dated on 2014-06-23: Mid-Day Market Movers For Monday, June 23, 2014

Financial news for AGIO dated on 2014-06-16: Agios Recieves Orphan Designation for AG-221

Financial news for AGIO dated on 2014-06-14: Agios Presents Positive Clinical Data from Ongoing Phase 1 Trial of AG-221 in Patients with Hematologic Malignancies at EHA

Financial news for AGIO dated on 2014-06-10: Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

Financial news for AGIO dated on 2014-05-22: Agios Pharmaceuticals to Present New Clinical Data from AG-221 Ongoing Phase 1 Study at the 19th Congress of EHA

Financial news for AGIO dated on 2014-05-14: Agios Pharmaceuticals Names Chris Bowden, M.D., as Chief Medical Officer

Financial news for AGIO dated on 2014-05-08: Agios Pharmaceuticals Reports Q1 EPS of \$(0.39) vs \$(0.38) Est; Revenue of \$8.41M vs \$7.30M Est

Financial news for AGIO dated on 2014-04-21: Agios Pharma Announces Public Offering of 2M Shares

Financial news for AGIO dated on 2014-04-17: Agios Initiates Phase 1 Study of AG-348

Financial news for AGIO dated on 2014-04-07: Market Wrap For April 7: Bears In Complete Control As Markets Get Hammered Yet Again

Financial news for AGIO dated on 2014-04-07: Mid-Afternoon Market Update: Markets Continue to Show Weakness as Defensive Names Come into Favor

Financial news for AGIO dated on 2014-04-07: Mid-Day Market Update: Dow Tumbles Over 100 Points; Intel Shares Rise Following Analyst Upgrade

Financial news for AGIO dated on 2014-04-07: Benzinga's Volume Movers

Financial news for AGIO dated on 2014-04-07: Mid-Morning Market Update: Markets Drop; Mallinckrodt To Acquire Questcor Pharmaceuticals For \$5.6B

Financial news for AGIO dated on 2014-04-07: Morning Market Movers

Financial news for AGIO dated on 2014-04-07: Benzinga's Top #PreMarket Gainers

Financial news for AGIO dated on 2014-04-07: JP Morgan Upgrades Agios Pharmaceuticals to Overweight, Raises PT to \$55.00

Financial news for AGIO dated on 2014-04-06: Agios Announces Initial Phase 1 AG-221 Data Presented at AACR 2014

Financial news for AGIO dated on 2014-03-19: Agios First Patient Enrolled in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

Financial news for AGIO dated on 2014-03-06: Mid-Afternoon Market Update: Markets Turn Up From the Lows, Fuel Cell Companies Show Weakness

Financial news for AGIO dated on 2014-03-06: Mid-Day Market Update: Costco Shares Decline After Weak Quarterly Results; Stage Stores Spikes Higher

Financial news for AGIO dated on 2014-03-06: Mid-Morning Market Update: Markets Open Higher; Staples Plans To Close 225 Stores

Financial news for AGIO dated on 2013-12-09: Agios Presents Preclinical Data from Lead Programs at ASH

Financial news for AGIO dated on 2013-11-15: Stocks Hitting 52-Week Lows

Financial news for AGIO dated on 2013-09-23: Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221

Financial news for AGIO dated on 2013-08-19: UPDATE: Goldman Sachs Initiates Agios Pharmaceuticals with Buy on Emerging Leadership Position

Financial news for AGIO dated on 2013-08-19: JP Morgan Initiates Coverage on Agios Pharmaceuticals at Neutral, Announces \$35.00 PT

Financial news for AGIO dated on 2013-08-19: Leerink Swann Initiates Coverage on Agios Pharmaceuticals at Outperform, Announces \$38.00 PT

Financial news for AGIO dated on 2013-08-19: Cowen & Company Initiates Coverage on Agios Pharmaceuticals at Outperform

Financial news for AGIO dated on 2013-08-19: Benzinga's Top Initiations

Financial news for AGIO dated on 2013-08-19: Goldman Sachs Initiates Coverage on Agios Pharmaceuticals at Buy, Announces \$37.00 PT

Financial news for AGIO dated on 2013-07-29: Agios Pharmaceuticals Closes Initial Public Offering, Underwriters Exercised Full Option

Financial news for AGIO dated on 2013-07-24: Mid-Afternoon Market Update: Agios Pharma Has Wildly Successful IPO Amid Red Markets

Financial news for AGIO dated on 2013-07-24: Shares of Agios Pharma Opens for Trade at \$29, Priced at \$18/Share

Financial news for AGIO dated on 2013-07-24: Shares of Agios Pharma to Open for Quote at 10:25AM EDT, Expected to Open for Trade at 10:40AM; Priced 5.88M Shares at \$18/Share

Financial news for AGIO dated on 2013-07-24: Agios Pharmaceuticals Prices 5.9M Share IPO at \$18.00/Share

Financial news for AGIO dated on 2013-07-16: Agios Pharma to Offer 5M Shares in \$14-16/Share Range in IPO, Will List on NASDAQ